Last Price$104.91.0%
Market Cap$154.5B
LTM ROIC - WACC
0.3%
5Y avg
10.2%
Medical - Devices industry
median
(61.1%)
Stock quality & Intrinsic value
7/10
(0.7%) overvalued
Boston Scientific Corporation ROIC - WACC
Annual
Quarterly
LTM
Industry median
Company stand-alone
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROIC - WACC | 4.8% | (22.8%) | (5.6%) | (10.7%) | (7.9%) | (8.8%) | (2.3%) | (27.3%) | (4.3%) | (2.1%) | (4.4%) | (1.6%) | (2.1%) | 4.3% | 179.1% | 0.8% | 4.5% | (1.5%) | 0.6% | (0.3%) |
Overvalued or undervalued?
Check the intrinsic value for BSX
and see if it's the right time to invest.
Boston Scientific Corporation (BSX) ROIC - WACC comparison analysis
General
LTM ROIC - WACC
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Boston Scientific CorporationBSX
0.3%
17.6%
16.7%
11.1%
Median Peer Set
4.6%
4.1%
126.3%
12.7%
Insulet CorporationPODD
19.5%
30.0%
4,364.6%
12.2%
Abbott LaboratoriesABT
17.6%
4.6%
134.5%
31.9%
Edwards Lifesciences CorporationEW
17.0%
(9.4%)
202.2%
76.7%
DexCom, Inc.DXCM
12.5%
11.3%
(1.4%)
14.3%
Stryker CorporationSYK
6.5%
10.2%
(5.8%)
13.2%
Align Technology, Inc.ALGN
2.7%
3.4%
26.0%
11.5%
Medtronic plcMDT
(0.4%)
3.6%
(2.1%)
11.4%
STERIS plcSTE
(1.1%)
3.6%
257.9%
7.4%
Zimmer Biomet Holdings, Inc.ZBH
(2.7%)
6.5%
253.2%
13.8%
Koninklijke Philips N.V.PHG
(10.3%)
(0.8%)
118.1%
(3.9%)
BSX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 6,283.0 11.7% | 7,821.0 24.5% | 8,357.0 6.9% | 8,050.0 (3.7%) | 8,188.0 1.7% | 7,806.0 (4.7%) | 7,622.0 (2.4%) | 7,249.0 (4.9%) | 7,143.0 (1.5%) | 7,380.0 3.3% | 7,477.0 1.3% | 8,386.0 12.2% | 9,048.0 7.9% | 9,823.0 8.6% | 10,735.0 9.3% | 9,913.0 (7.7%) | 11,888.0 19.9% | 12,682.0 6.7% | 14,240.0 12.3% | 16,747.0 17.6% |
| Cost of Goods Sold (COGS) | 1,386.0 | 2,207.0 | 2,342.0 | 2,469.0 | 2,576.0 | 2,599.0 | 2,659.0 | 2,502.0 | 2,314.0 | 2,321.0 | 2,243.0 | 2,503.0 | 2,661.0 | 2,883.0 | 3,181.0 | 3,510.0 | 3,760.0 | 4,003.0 | 4,345.0 | 5,257.0 |
% margin | 4,897.0 77.9% | 5,614.0 71.8% | 6,015.0 72.0% | 5,581.0 69.3% | 5,612.0 68.5% | 5,207.0 66.7% | 4,963.0 65.1% | 4,747.0 65.5% | 4,829.0 67.6% | 5,059.0 68.6% | 5,234.0 70.0% | 5,883.0 70.2% | 6,387.0 70.6% | 6,940.0 70.7% | 7,554.0 70.4% | 6,403.0 64.6% | 8,128.0 68.4% | 8,679.0 68.4% | 9,895.0 69.5% | 11,490.0 68.6% |
| Operating Expenses | 3,653.0 | 4,444.0 | 5,768.0 | 7,039.0 | 6,410.0 | 4,217.0 | 3,252.0 | 3,816.0 | 3,945.0 | 4,157.0 | 4,244.0 | 4,564.0 | 4,856.0 | 5,281.0 | 5,814.0 | 5,719.0 | 6,304.0 | 6,646.0 | 7,552.0 | 8,887.0 |
| Research & Development Expenses (R&D) | 680.0 | 1,008.0 | 1,091.0 | 1,006.0 | 1,035.0 | 939.0 | 895.0 | 886.0 | 861.0 | 817.0 | 876.0 | 920.0 | 997.0 | 1,113.0 | 1,174.0 | 1,143.0 | 1,204.0 | 1,323.0 | 1,414.0 | 1,615.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,814.0 | 2,675.0 | 2,909.0 | 2,566.0 | 4,848.0 | 2,765.0 | 2,659.0 | 2,535.0 | 2,674.0 | 2,902.0 | 2,873.0 | 3,099.0 | 3,294.0 | 3,569.0 | 3,941.0 | 3,787.0 | 4,359.0 | 4,520.0 | 5,190.0 | 5,984.0 |
% margin | 968.0 15.4% | (2,949.0) (37.7%) | (14.0) (0.2%) | (1,536.0) (19.1%) | (894.0) (10.9%) | (656.0) (8.4%) | 904.0 11.9% | (3,868.0) (53.4%) | 120.0 1.7% | 299.0 4.1% | (327.0) (4.4%) | 447.0 5.3% | 1,285.0 14.2% | 1,506.0 15.3% | 1,518.0 14.1% | 1,044.0 10.5% | 2,043.0 17.2% | 1,649.0 13.0% | 2,343.0 16.5% | 2,603.0 15.5% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 13.0 | 7.0 | 5.0 | 6.0 | 5.0 | 5.0 | 5.0 | 5.0 | 3.0 | 30.0 | 3.0 | 4.0 | 10.0 | 22.0 | 107.0 |
| Interest Expense | 0.0 | 0.0 | 570.0 | 468.0 | 407.0 | 393.0 | 281.0 | 261.0 | 324.0 | 216.0 | 284.0 | 233.0 | 229.0 | 241.0 | 473.0 | 361.0 | 341.0 | 470.0 | 265.0 | 305.0 |
| Pre-tax Income | 891.0 | (3,535.0) | (569.0) | (2,062.0) | (1,308.0) | (1,063.0) | 642.0 | (4,107.0) | (223.0) | 91.0 | (650.0) | 177.0 | 933.0 | 1,422.0 | 687.0 | (138.0) | 1,076.0 | 1,141.0 | 1,985.0 | 2,282.0 |
% effective tax rate | 263.0 29.5% | 42.0 (1.2%) | (74.0) 13.0% | 10.0 (0.5%) | (283.0) 21.6% | 2.0 (0.2%) | 201.0 31.3% | (39.0) 0.9% | (102.0) 45.7% | (176.0) (193.4%) | (411.0) 63.2% | (170.0) (96.0%) | 828.0 88.7% | (249.0) (17.5%) | (4,013.0) (584.1%) | 2.0 (1.4%) | 36.0 3.3% | 443.0 38.8% | 393.0 19.8% | 436.0 19.1% |
% margin | 628.0 10.0% | (3,577.0) (45.7%) | (495.0) (5.9%) | (2,072.0) (25.7%) | (1,025.0) (12.5%) | (1,065.0) (13.6%) | 441.0 5.8% | (4,068.0) (56.1%) | (121.0) (1.7%) | 267.0 3.6% | (239.0) (3.2%) | 347.0 4.1% | 104.0 1.1% | 1,671.0 17.0% | 4,700.0 43.8% | (140.0) (1.4%) | 1,041.0 8.8% | 698.0 5.5% | 1,593.0 11.2% | 1,853.0 11.1% |
| EPS | 0.76 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.26 | 0.08 | 1.21 | 3.38 | (0.10) | 0.69 | 0.45 | 1.08 | 1.26 |
| Diluted EPS | 0.75 | (2.81) | (0.33) | (1.38) | (0.68) | (0.70) | 0.29 | (2.89) | (0.09) | 0.20 | (0.18) | 0.25 | 0.07 | 1.19 | 3.33 | (0.10) | 0.69 | 0.45 | 1.07 | 1.25 |
% margin | 1,295.0 20.6% | (2,319.0) (29.7%) | 940.0 11.2% | (699.0) (8.7%) | (108.0) (1.3%) | 149.0 1.9% | 1,635.0 21.5% | (3,161.0) (43.6%) | 721.0 10.1% | 433.0 5.9% | 360.0 4.8% | 1,226.0 14.6% | 2,007.0 22.2% | 2,585.0 26.3% | 2,210.0 20.6% | 1,511.0 15.2% | 2,518.0 21.2% | 2,741.0 21.6% | 3,453.0 24.2% | 2,603.0 15.5% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Boston Scientific Corporation's ROIC - WACC?
As of today, Microsoft Corp's last 12-month ROIC - WACC is 0.3%, based on the financial report for Dec 31, 2024 (Q4’2024). The average annual ROIC - WACC for Boston Scientific Corporation have been (0.4%) over the past three years, and 10.7% over the past five years.
2) Is Boston Scientific Corporation's ROIC - WACC Good?
As of today, Boston Scientific Corporation's ROIC - WACC is 0.3%, which is higher than industry median of (61.1%). It indicates that Boston Scientific Corporation's ROIC - WACC is Good.